RESEARCH MONOGRAPH · KDC-MN-356

Cetirizine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

85/100

Second-gen H1 thats genuinely peripherally selective, one of the cleanest antihistamines on the market

Cetirizine is what diphenhydramine wishes it was. Selective H1 antagonist, minimal anticholinergic activity, low CNS penetration relative to first-generation H1 blockers, and clean pharmacokinetics with a 10-hour-ish half-life that makes once-daily dosing reasonable.

The selectivity story matters. Cetirizine is the carboxylic acid metabolite of hydroxyzine, and the COOH group reduces blood-brain barrier penetration substantially. Which is why the sedation profile, while not zero (about 10 to 15 percent of patients report some sedation at standard doses, which is higher than fexofenadine), is much milder than diphenhydramine. Levocetirizine, the active R-enantiomer, has even cleaner pharmacology and is what most modern research uses prefer.

What's worth noting from a research angle is the recent attention on cetirizine withdrawal pruritus, where some patients on long-term daily cetirizine develop severe itching when they stop. The mechanism isn't fully nailed but probably involves H1 receptor upregulation during chronic blockade. There's a small but real signal in the dermatology literature and it's the kind of phenomenon that bears on broader questions about chronic receptor antagonism.

For research purposes, cetirizine is a useful peripheral H1 probe. The eosinophil migration inhibition, the mast cell stabilization (modest, but real), and the chronic urticaria efficacy data make it a workhorse in allergy and immune research.

Sourcing is excellent. Standard small molecule, the dihydrochloride is widely available, levocetirizine versus racemate is the main choice to make for research. USP and EP reference standards both exist.

What we like is the receptor selectivity and the pharmacokinetic predictability. The metabolism is largely renal (around 70 percent unchanged), which simplifies interaction profiles compared to CYP-heavy alternatives.

What we dont love is the marketing positioning of cetirizine as completely non-sedating, which doesn't quite match the 10-percent-ish sedation rate in trials. Honestly fexofenadine is cleaner on that axis if true non-sedation matters for a research design.

Staying power as a tool compound is high. Selective H1 probes are basic pharmacology infrastructure.

Evidence: 90
Mechanism: 88
Reliability: 88
Safety: 90
Sourcing: 92
Value: 90
Signal: 65
Staying power: 78

Plain-language summary Intrigue 46 / 100

Cetirizine, sold as Zyrtec, is a second-generation H1 antihistamine that mostly stays out of the brain because of a carboxylic acid group that prevents blood-brain barrier penetration. That structural feature gives the drug efficacy comparable to diphenhydramine for allergic rhinitis and urticaria with much less sedation and almost no anticholinergic effects. It is the active metabolite of hydroxyzine, isolated and developed as a standalone compound. Cetirizine is the most sedating of the second-generation antihistamines (about 10 to 15 percent of users report drowsiness), but still vastly cleaner than first-generation alternatives. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Second-generation H1 antihistamine (peripheral)

A second-generation peripheral H1 antihistamine; the principal active metabolite of hydroxyzine without CNS penetration.

Abstract

Cetirizine (2-[2-[4-[(R/S)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl]ethoxy]acetic acid; CAS 83881-51-0; molecular formula C21H25ClN2O3; molecular weight 388.89) is a second-generation H1 antihistamine developed at UCB and approved by the FDA in 1995 (Zyrtec). The compound is the principal active carboxylic acid metabolite of hydroxyzine; the addition of the carboxyl group eliminates blood-brain barrier penetration, producing peripheral H1 antagonism without the central sedating effects of hydroxyzine. H1 selectivity is high; minimal anticholinergic activity. Plasma half-life is approximately 8 hours; minimal hepatic metabolism (excreted largely unchanged renally). The compound has minor sedating effect in approximately 10 to 15 percent of users (slightly more than fexofenadine or loratadine), reflecting some BBB penetration. Approved indications: allergic rhinitis, urticaria, allergic conjunctivitis. Used as the canonical second-generation peripheral H1 antagonist in research.

Mechanism of action

Second-generation H1 antagonist with peripheral selectivity (carboxyl group prevents BBB penetration). Minimal anticholinergic and sedating activity.

Reported research dose ranges

Clinical 10 mg in the published literature.

References

Spencer CM, et al. Cetirizine: a reappraisal. Drugs 1993.
Snowman AM, Snyder SH. Cetirizine: actions on neurotransmitter receptors. J Allergy Clin Immunol 1990.
Simons FE. Comparative pharmacology of H1 antihistamines: clinical relevance. Am J Med 2002.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-356

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Cetirizine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs